乳腺肿块的补充光声成像:成本-效果分析
本研究采用决策树模型,从美国医疗系统角度比较补充光声超声(OA/US)与单用灰阶超声(US)鉴别乳腺肿块良恶性的成本-效果。基于PIONEER-01试验(NCT01943916)的诊断性能和Truven Health MarketScan数据库的成本参数,OA/US的增量净货币效益为1495.36美元,ICER为-31715.82美元/QALY,提示OA/US更具成本-效果,主要归因于减少假阳性导致的良性活检。
要点
- 在诊断场景中,补充OA/US较单用US更具成本-效果(ICER为-31715.82美元/QALY)。
- OA/US主要通过减少假阳性结果及后续良性活检来降低成本并改善生活质量。
- 当OA/US成本超过1030.61美元或敏感度低于79.7%或特异度低于30.5%时,单用US策略的净货币效益更高。
核心结论
- 在诊断场景中,补充OA/US鉴别乳腺肿块良恶性比单用US更具成本-效果,可降低成本并改善患者生活质量,主要归因于减少假阳性结果及后续良性活检。
研究设计与样本
- 决策树模型,从美国医疗系统角度比较OA/US与US的成本-效果,诊断性能参数来自PIONEER-01临床试验(NCT01943916),成本参数来自Truven Health MarketScan数据库,效用值依据已发表的患者报告结局确定,采用马尔可夫链模型计算ICER和NMB,并进行确定性和概率敏感性分析,支付意愿阈值为100000美元/QALY。
诊断标准与关键数值
- OA/US的25年累积成本为16617.36美元,产出16.85 QALYs;增量NMB为1495.36美元,ICER为-31715.82美元/QALY;确定性敏感性分析中,当OA/US成本超过1030.61美元、敏感度低于79.7%或特异度低于30.5%时,单用US策略的NMB更高;概率敏感性分析中,在10000次迭代中OA/US在98.69%的情况下为更优策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To evaluate the cost-effectiveness of utilizing supplemental optoacoustic ultrasound (OA/US) versus gray-scale ultrasound (US) alone to differentiate benign and malignant breast masses in a diagnostic setting.
MATERIALS AND METHODS: We created a decision-tree model to compare the cost-effectiveness of OA/US and US from the perspective of the US healthcare system. We utilized diagnostic test performance parameters from the PIONEER-01(NCT01943916) clinical trial and cost parameters (USD) from the Truven Health MarketScan Databases. Utility (quality adjusted life year, QALY) values were determined following published patient-reported outcomes. Cost-effectiveness was calculated through incremental cost-effectiveness ratio (USD/QALY, ICER) and net monetary benefit (NMB) in a Markov chain model. Deterministic and probabilistic sensitivity analyses were performed to determine the significance of variation in input parameters. A willingness-to-pay (WTP) threshold of $100,000/QALY was used for the study.
RESULTS: OA/US had an estimated cumulative cost of $16,617.36 and the outcome of 16.85 QALYs in the 25-year period. The incremental NMB for OA/US was $1495.36, and the ICER was -$31,715.82/QALY, indicating that supplemental use of OA/US was more cost-effective than US alone. In the deterministic sensitivity analysis, when the cost of OA/US exceeded $1030.61 or the sensitivity of OA/US fell below 79.7%, or the specificity fell below 30.5%, the US alone strategy yielded higher NMB values compared to supplemental OA/US. According to probabilistic sensitivity analysis, OA/US was the better strategy in 98.69% of 10,000 iterations.
CONCLUSION: OA/US is more cost-effective than US to differentiate benign or malignant breast masses in the diagnostic setting. It can reduce costs while improving patients' quality of life, primarily by reducing false-positive results with consequent benign biopsies.
引用
- Ozcan BB, Xi Y, Dogan BE, et al. Supplemental Optoacoustic Imaging of Breast Masses: A Cost-Effectiveness Analysis. Acad Radiol. 2023. PMID: 37748954. doi:10.1016/j.acra.2023.08.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。